The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)

Efficacy of second line (2L) treatment with tivozanib (Tivo) as monotherapy or with nivolumab (Nivo) in patients (pts) with metastatic renal cell carcinoma (mRCC) previously treated with an immune checkpoint inhibitor (ICI) combination of ipilimumab (Ipi)/Nivo or vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFR-TKI)/ICI in the phase 3 TiNivo-2 study.

Alex  Chehrazi-Raffle

Honoraria - ASCO; EPG Health; Medical Oncology Association of Southern California; OncLive/MJH Life Sciences

Consulting or Advisory Role - Aveo Inc; Eisai; Exelixis; Seagen

Speakers' Bureau - Exelixis

Research Funding - Exelixis

Travel, Accommodations, Expenses - Bayer

Robert  Motzer

Consulting or Advisory Role - Aveo; EMD Serono; Exelixis; Incyte; Merck; Takeda

Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Eisai (Inst); Exelixis (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb

Katy  Beckermann

Consulting or Advisory Role - Adicet Bio; Alpine Immune Sciences; Aravive; Arcus Biosciences; AstraZeneca; AVEO; Bristol-Myers Squibb; Eisai; Exelixis; Merck; Nimbus Therapeutics; Xencor

Research Funding - Aravive (Inst); ArsenalBio (Inst); Bristol-Myers Squibb; Pionyr (Inst)

Philippe  Barthelemy

Honoraria - Astellas Pharma; AstraZeneca; Bayer; BMS; Gilead Sciences; IPSEN; Janssen-Cilag; Merck KGaA; MSD; Novartis; Pfizer

Consulting or Advisory Role - AAA/Endocyte/Novartis; Amgen; AstraZeneca; Bayer; BMS; Eisai; Gilead Sciences; ipsen; Janssen-Cilag; Merck KGaA; MSD Oncology; Pfizer

Research Funding - IPSEN (Inst)

Travel, Accommodations, Expenses - BMS; IPSEN; Janssen-Cilag; Merck/Pfizer; MSD; Pfizer

Roberto  Iacovelli

Honoraria - Astellas Pharma; IPSEN; MSD; Pfizer

Consulting or Advisory Role - AAA/Endocyte/Novartis; Astellas Pharma; Bayer; Eisai; Genenta Science; Janssen; Merck; MSD; Novartis; Pfizer; Sanofi

Speakers' Bureau - Ipsen; Janssen; MSD; Pfizer; Sanofi

Research Funding - Bristol-Myers Squibb/Celgene (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Ipsen; Janssen; MSD; Pfizer

Sheik  Emambux

Consulting or Advisory Role - Bristol-Myers Squibb/Pfizer; Eisai; MSD

Travel, Accommodations, Expenses - Chugai Pharma; Janssen Oncology; MSD; Pfizer

Javier  Molina Cerrillomd

Consulting or Advisory Role - Adium Pharma; Advanced Accelerator Applications; Astellas Pharma; BMS; Eisai; Ipsen; Janssen; MSD; Pfizer; Sanofi

Speakers' Bureau - BMS; Ipsen; Pfizer

Research Funding - Ipsen (Inst); Janssen (Inst); Pfizer (Inst)

Travel, Accommodations, Expenses - Ipsen

Benjamin  Garmezy

Research Funding - Abbvie (Inst); Accutar Biotech (Inst); Arcus Biosciences (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); crispr therapeutics (Inst); Eikon Therapuetics (Inst); Envision Pharma Group (Inst); Exelixis (Inst); Flare Therapeutics (Inst); Genentech (Inst); Harbour BioMed (Inst); IDEAYA Biosciences (Inst); Janssen Oncology (Inst); Janux Therapeutics (Inst); Jubilant Therapeutics (Inst); Kineta (Inst); Kinnate Biopharma (Inst); Loxo (Inst); Loxo/Lilly (Inst); MiNK Therapeutics (Inst); Nuvation Bio (Inst); ProfoundBio (Inst); Roche/Genentech (Inst); Takeda (Inst); Teon Therapeutics (Inst); Tmunity Therapeutics, Inc. (Inst); Xencor (Inst); Xencor (Inst); Zenshine (Inst); Zenshine (Inst)

(OPTIONAL) Uncompensated Relationships - Abbvie (Inst); Adaptimmune (Inst); Adicet Bio (Inst); AIQ Global (Inst); Amgen (Inst); Arcus Biosciences (Inst); Arvinas (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); Eisai (Inst); EMD Serono (Inst); Exelixis (Inst); Janssen (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Rondo Therapeutics (Inst); Sanofi (Inst); Seagen (Inst); Xencor (Inst)

Pedro  Barata

Stock and Other Ownership Interests  - Luminate Medical

Honoraria - UroToday

Consulting or Advisory Role - Astellas Medivation; AstraZeneca; AVEO; Bayer; BMS; Caris Life Sciences; Dendreon (Inst); Eisai; EMD Serono; Exelixis; Ipson; Merck; Novartis; Pfizer

Speakers' Bureau - AstraZeneca; Bayer (Inst); Caris Life Sciences (Inst); Merck; Pfizer/Astellas (Inst)

Research Funding - AVEO (Inst); Blue Earth Diagnostics (Inst); Exelixis; Merck (Inst); Pfizer (Inst)

Rana  McKay

Consulting or Advisory Role - Ambrx; Arcus Biosciences; Astellas Medivation; AstraZeneca; AVEO; Bayer; Blue Earth Diagnostics; Bristol Myers Squibb; Calithera Biosciences; Caris Life Sciences; Daiichi Sankyo; Dendreon; Esiai; Exelixis; Janssen; Lilly; Merck; Myovant Sciences; NeoMorph; Novartis; Pfizer; Sanofi; Seagen; Sorrento Therapeutics; Sumitomo Pharma Oncology; Telix Pharmaceuticals; Tempus; Vividion Therapeutics

Research Funding - Artera (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol Myers Squibb (Inst); Exelixis (Inst); Oncternal Therapeutics (Inst); Tempus (Inst)

Hans  Hammers

Honoraria - Bristol-Myers Squibb

Consulting or Advisory Role - ARMO BioSciences; Bayer; Bristol-Myers Squibb; Corvus Pharmaceuticals; exelixis; Lilly; Merck; Novartis; Pfizer; Surface Oncology

Research Funding - Aveo (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Hibercell (Inst); Merck (Inst); NGM Biopharmaceuticals (Inst); NiKang Therapeutics (Inst); Surface Oncology (Inst); Werewolf Therapeutics (Inst)

Travel, Accommodations, Expenses - Bristol-Myers Squibb; Lilly; Merck; Novartis; Pfizer

Daniel  Heng

Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Eisai; Ipsen; Janssen; Merck; Novartis; Pfizer

Research Funding - Bristol-Myers Squibb (Inst); Exelixis (Inst); Ipsen (Inst); Novartis (Inst); Pfizer (Inst)

Bo  Jin

Employment - AVEO; SinoCellTech Group Ltd.; Sumitomo Pharma Oncology

Stock and Other Ownership Interests  - SinoCellTech Group Ltd.

Claudia  Lebedinsky

Employment - AVEO; Sumitomo Dainnipon Pharma Oncology

Consulting or Advisory Role - Sumitomo Pharma Oncology

Patents, Royalties, Other Intellectual Property - US patent application submitted, title: Methods of treating myeloproliferative neoplasms. Pending patent.

Edgar  Braendle

Employment - NewYork-Presbyterian/Columbia University Irving Medical Center (I)

Stock and Other Ownership Interests  - Autolus Ltd The Mediaworks 191 Wood Lane White City London W12 7FP

Consulting or Advisory Role - Autolus Ltd The Mediaworks 191 Wood Lane White City London W12 7FP

Bradley  McGregor

Consulting or Advisory Role - Arcus Biosciences; Astellas Pharma; AVEO; Bristol-Myers Squibb; Daiichi Sankyo/Astra Zeneca; Eisai; Exelixis; Genmab; Gilead Sciences; Hexagon; Loxo/Lilly; Pfizer; Seattle Genetics/Astellas

Research Funding - Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Exelixis (Inst); Pfizer/EMD Serono (Inst); Seattle Genetics/Astellas (Inst)

Laurence  Albiges

Consulting or Advisory Role - Astellas Pharma (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Daiichi Sankyo Europe GmbH (Inst); Eisai (Inst); Ipsen (Inst); Janssen (Inst); Merck (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Telix Pharmaceuticals (Inst)

Travel, Accommodations, Expenses - BMS; Ipsen; MSD; Pfizer

Toni  Choueiri

Leadership - ASCO

Stock and Other Ownership Interests  - Abalytics Oncology; Bicycle Therapeutics; Curesponse; Faron Pharmaceuticals; Inndura; Osel; Pionyr; Precede Bio; Primium; Tempest Therapeutics

Honoraria - Alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bristol-Myers Squibb; Clinical Care Options; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; HiberCell; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; MashupMD; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate

Consulting or Advisory Role - alkermes; Analysis Group; Aravive; Arcus Biosciences; ASCO; AstraZeneca; Bayer; Bicycle Therapeutics; Bristol-Myers Squibb; Clinical Care Options; Curesponse; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; Gilead Sciences; Gilead Sciences; GlaxoSmithKline; Harborside Press; Infinity Pharmaceuticals; Ipsen; Janssen Oncology; Kanaph Therapeutics; Lancet Oncology; Lilly; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Neomorph; NiKang Therapeutics; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Precede Bio; Prometheus; Roche/Genentech; Sanofi/Aventis; Scholar Rock; Tempest Therapeutics; The New England Journal of Medicine; UpToDate

Research Funding - Agensys (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); AVEO (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Eisai (Inst); Exelixis (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Merck (Inst); NiKang Therapeutics (Inst); Novartis (Inst); Peloton Therapeutics (Inst); Pfizer (Inst); Roche (Inst); Roche/Genentech (Inst); Seattle Genetics/Astellas (Inst); Takeda (Inst); TRACON Pharma (Inst)

Patents, Royalties, Other Intellectual Property - -International Patent Application No. PCT/US2018/058430, entitled “Biomarkers of Clinical Response and Benefit to Immune Checkpoint Inhibitor Therapy (Inst); ctDNA technologies; International Patent Application No. PCT/US2018/12209, entitled “PBRM1 Biomarkers Predictive of Anti-Immune Checkpoint Response (Inst)

Travel, Accommodations, Expenses - Alexion Pharmaceuticals; alligent; Analysis Group; AstraZeneca; Bayer; Bristol-Myers Squibb; Cerulean Pharma; Clinical Care Options; Corvus Pharmaceuticals; Eisai; EMD Serono; ESMO; Exelixis; Foundation Medicine; GlaxoSmithKline; Harborside Press; HERON; Ipsen; Kidney Cancer Association; Lancet Oncology; Lilly; Lpath; Merck; Michael J. Hennessy Associates; Navinata Health; NCCN; Novartis; Peloton Therapeutics; Pfizer; PlatformQ Health; Prometheus; Roche/Genentech; Sanofi/Aventis; The New England Journal of Medicine; UpToDate

Other Relationship - OTHER MEDICAL COMMUNICATION COMPANIES